Annual Product Quality Review is the single largest recurring compliance documentation exercise in pharmaceutical quality—and it is overwhelmingly manual at most companies. QA teams spend months compiling data from disconnected systems, assembling spreadsheets, and producing reports that are already stale by the time they are complete. Celestara transforms APQR from a reactive annual burden into continuous product quality monitoring, with AI agents that aggregate data in real time, detect adverse trends as they emerge, and generate audit-ready reports on demand.
Key Highlights
Regulatory Context
The firm’s annual product reviews did not define batches manufactured during the year being reviewed. There was no documented evidence of rejected batches, complaint investigations, recalls, returned batches, or manufacturing/laboratory investigations. The APR lacked specificity and focused only on an assessment of applicable procedures rather than actual product quality data.
The firm does not maintain written records for annual product reviews conducted for aseptically produced drug products. Over 14 product formulations—including Amiodarone, Heparin, Vancomycin, and Norepinephrine—had no APR documentation, leaving no evidence that quality standards were evaluated annually.
The Quality Unit failed to ensure drug products sold into the US market are stable throughout their labelled shelf life. No testing program was established to assess stability characteristics, meaning critical trending data for APQR—long-term and accelerated stability results, adverse trends, and shelf-life projections—simply did not exist.
Environmental monitoring data was manually entered from collection sheets into uncontrolled electronic spreadsheets used to generate reports and graphical analyses. Multiple discrepancies were identified between source data and reports. Trend analysis summary reports contained inaccurate mold recovery data, excluded relevant deviations, and had mislabeled graphs—making CAPA effectiveness assessment impossible.
The firm failed to calculate and document yield percentages for approximately hundreds of packaging batches destined for the US market. Percent yields were not calculated, documented, or reviewed for any potential issues with the specific and separate packaging operation of each batch—data that is a core component of any meaningful annual product review.
During stability data review of several OTC products, the firm failed to test stability samples at required intervals. The written stability testing program was not followed, meaning APQR had no reliable stability data to evaluate whether products remained within specification throughout their shelf life.
The Problem
Annual Product Quality Review in Celestara
Celestara continuously pulls batch yields, analytical results, deviations, CAPAs, complaints, stability data, and environmental monitoring from all connected systems. When APQR time arrives, the data is already there—normalized, validated, and complete.
AI generates control charts, calculates Cpk/Ppk indices, and performs trend analysis across all critical quality attributes for every batch—not at the end of the year, but continuously. Adverse trends trigger alerts the moment they emerge.
The platform monitors all ongoing stability studies, flags out-of-trend results before they become out-of-specification, and projects shelf-life trajectories. Every stability data point is automatically linked to its product APQR.
Celestara correlates quality data across products that share equipment, raw materials, or processes. When a yield drift affects multiple products on the same line, the system connects the dots—turning isolated observations into systemic insights.
When the review period ends, Celestara generates a complete APQR draft with all required data elements, statistical visualizations, narrative summaries, and regulatory-specific formatting—ready for QA review and approval, not weeks of manual assembly.
The Solution
Purpose-built tools that address both the FDA compliance gaps and the operational barriers to effective annual product quality review.
Celestara continuously aggregates data from all connected systems—and unlike standard reporting tools, its AI agents can extract insights from scanned batch records, free-text deviation narratives, handwritten logbooks, and PDF reports. When the review period ends, every data element is already collected, normalized, and validated.
AI generates control charts, calculates process capability indices (Cpk/Ppk), and performs continuous trend detection across all critical quality attributes. Adverse trends are flagged the moment they emerge—not months later during annual compilation.
Deploy consistent APQR templates, statistical methodologies, and approval workflows across all facilities. Every site follows the same review process, making cross-site trending meaningful and regulatory submissions consistent.
Monitor how FDA cites APQR deficiencies across the industry. Understand which review gaps draw 483s—from missing stability data to inadequate statistical trending—so your team knows exactly what inspectors evaluate first.
Results
Real results from organizations using Celestara for annual product quality review
Next Step
Stop spending months compiling annual reviews from spreadsheets. Celestara continuously aggregates quality data from all your systems, performs real-time statistical trending, and generates audit-ready APQR reports on demand—transforming a reactive compliance exercise into continuous product quality intelligence.
Get Started